High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA

triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol 2011; 41: 172–179. 10. Alexander BM, Sprott K, Farrow DA et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010; 16: 5796–5804. 11. Mehta R, Jain RK, Sneige N et al. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol 2010; 63: 744–747. 12. Goll DE, Thompson VF, Li H et al. The calpain system. Physiol Rev 2003; 83: 731–801. 13. Storr SJ, Carragher NO, Frame MC et al. The calpain system and cancer. Nat Rev Cancer 2011; 11: 364–374. 14. Storr SJ, Woolston CM, Barros FF et al. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. Int J Cancer 2010; 129: 1773–1780. 15. Storr SJ, Mohammed RA, Woolston CM et al. Calpastatin is associated with lymphovascular invasion in breast cancer. Breast 2011; 20: 413–418. 16. Libertini SJ, Robinson BS, Dhillon NK et al. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res 2005; 65: 10700–10708. 17. Agarwal R, Gonzalez-Angulo AM, Myhre S et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009; 15: 3654–3662. 18. Heiser LM, Sadanandam A, Kuo WL et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 2012; 109: 2724–2729. 19. Abdel-Fatah TM, Powe DG, Agboola J et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2010; 220: 419–434. 20. Rakha EA, El-Rehim DA, Paish C et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149–3156. 21. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005; 2: 416–422. 22. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340–350. 23. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252–7259. 24. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368–1376. 25. Glading A, Uberall F, Keyse SM et al. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001; 276: 23341–23348. 26. Xu L, Deng X. Protein kinase Ciota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of microand m-calpains. J Biol Chem 2006; 281: 4457–4466. 27. Neumar RW, Meng FH, Mills AM et al. Calpain activity in the rat brain after transient forebrain ischemia. Exp Neurol 2001; 170: 27–35. 28. Goncalves I, Nitulescu M, Saido TC et al. Activation of calpain-1 in human carotid artery atherosclerotic lesions. BMC Cardiovasc Disord 2009; 9: 26.